Bharat Biotech’s Covid-19 Vaccine Covaxin Phase 3 Study Gets Mixed Review From Lancet
Extrapolating from the report, Lancet said 'two doses offer 77.8% protection against…
Bharat Biotech Ramps Up Covaxin Capacity To 500 Million Doses A Year
Hyderabad, NFAPost: Vaccine maker Bharat Biotech in April expanded its Covaxin-manufacturing capacity…
DCGI Approves Bharat Biotech’s Covaxin Trials For Children
For the first time in the world, a Covid vaccine will be…
Covaxin’s Phase 1 Trial Data Shows Robust Response: Bharat Biotech
Bengaluru, NFAPost: Indigenous vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech International…
